StockData
Eikon Therapeutics, Inc. logo

Eikon Therapeutics, Inc. (EIKN) company profile

EIKNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$5.15−0.23 (-4.36%)

Close on Nov 17, 2026Market cap $278.95MP/E –Yield –

About Eikon Therapeutics

Biological Products, (No Diagnostic Substances), SIC 2836

Eikon Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops treatments for oncology indications and neurological diseases. The company utilizes a proprietary technology platform centered on single-molecule tracking to discover therapies, while also in-licensing external clinical assets. Its oncology pipeline features EIK1001, an immune-stimulating dual agonist for melanoma and lung cancer; EIK1003 and EIK1004, selective PARP1 inhibitors for various solid tumors; and EIK1005, a Werner helicase inhibitor. Because its candidates are experimental, the company has no marketed products or commercial customers, focusing its treatments on patient populations participating in clinical studies.

The company maintains its principal executive offices in Millbrae, California. Operating on an international scale, the organization runs clinical trials across multiple continents, including North America, Europe, Asia, Africa, and Oceania. Its active study locations span numerous countries such as the United States, Australia, Canada, China, South Korea, South Africa, Israel, New Zealand, and more than a dozen European nations, including the United Kingdom, Germany, France, and Spain.

Summary of the business section of Eikon Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Eikon Therapeutics, Inc.
Headquarters
Millbrae, CA
Address
230 Harriet Tubman Way 94030
Phone
(341) 777-0566
Employees
384, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31

Stock & identifiers

Ticker
EIKN
Exchange
Nasdaq
IPO date
Feb 5, 2026
Shares outstanding
54M, Aug 3, 2026
Filer category
<br>Emerging growth company
SEC CIK
1861123
CUSIP
282564103
ISIN
US2825641036
FIGI
BBG00T0XRJ75
Share class FIGI
BBG00T0XRJ84
EIN
84-2807586

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Roger M. PerlmutterSee remarks, Director1,475,856
Roy D. BaynesChief Medical Officer–
Michael A. KlobucharChief Operating Officer–
Benjamin Bruno ThornerSee Remarks–
Alfred Lloyd Bowie Jr.Chief Financial Officer51,572
Ma. Fatima FranciscoDirector–
Kenneth C. FrazierDirector111,111
Robert Luther HuffinesDirector–
Josh WolfeDirector2,387,705
David W. MelineDirector–
Leon ChenDirector–

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Feb 5, 2026
Offer price
$18.00
Securities offered
21,177,600
Gross proceeds
$381.20M
Exchange
Nasdaq
First trading day
Feb 5, 2026
First-day close
$15.00-16.7%
Lock-up ends (est.)
Aug 4, 2026

“The initial public offering price is $18.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Corporate history

Events identified from SEC filings

See a number that looks wrong?